Key result
Compared with non-diabetic patients, patients with diabetes post-MI had a higher risk of a composite of cardiovascular events (14% vs 7%; HR 1.63, 95% CI 1.01-2.64, P=0.045).
Why the study?
Does diabetes influence cardiac remodeling and clinical outcomes, and does aliskiren improve LV size in diabetic patients post-MI with LVEF ≤ 45%?
RCT (n=820)
placebo-controlled
randomized
Does diabetes influence cardiac remodeling and clinical outcomes, and does aliskiren improve LV size in diabetic patients post-MI with LVEF ≤ 45%?
Hazard Ratio: 1.63 (95% CI 1.01–2.64)
Absolute Event Rate: 14% vs 7%
p-value: p=0.045
Diabetic patients post-MI with LV dysfunction have increased CV risk and greater diastolic dysfunction and concentric remodeling compared to non-diabetics, despite similar systolic impairment.
No takes yet. Share an insight, caveat, or question.
Diabetics post-MI with LV dysfunction warrant closer CV surveillance; confirms higher risk and concentric remodeling while leaving aliskiren's ESV benefit open.
Shah et al. (2011) conducted an RCT in myocardial infarction (n=820). Diabetes vs. Non-diabetic patients was evaluated on composite of cardiovascular (CV) death, heart failure hospitalization, recurrent MI, stroke, or aborted sudden death (HR 1.63, 95% CI 1.01-2.64, p=0.045). Compared with non-diabetic patients, patients with diabetes post-MI had a higher risk of a composite of cardiovascular events (14% vs 7%; HR 1.63, 95% CI 1.01-2.64, P=0.045).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: